Satipharm begins clinical trial of CBD capsules for treating menopause
Category: #health  By Saipriya Iyer  Date: 2020-02-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Satipharm begins clinical trial of CBD capsules for treating menopause

Cannabis was prior considered to possess various medicinal benefits for treating diseases. However, after years of restriction, the scientific community is finally exploring the medical avenues of CBD by conducting advanced clinical trials and creating new formulations.

Recently, Satipharm Ltd., a wellness and health firm, took a pioneering step towards this direction by initiating a clinical research on CBD capsules for offering patients the needed relief from menopause symptoms.

After the fruitful conclusion of Phase II clinical study indicating that Satipharm CBD capsules minimized seizures in kids with an average 73% of treatment-resistant epilepsy, the company is reportedly shifting its focus towards menopause and perimenopause.

Reports cite that using these advanced CBD capsules along with Gelpell® delivery technology, which is developed under Good Manufacturing Practice ("GMP"), would allow Satipharm to validate its patented CBD formulation as it offers substantial relief from physiological-based symptoms.

Speaking on the move, Jonathan Hartshorn, CEO, Satipharm, said that delivering clinical proof to its users, upon which they can rely on to take their healthcare decisions, has been a key objective for Satipharm.

After the success of its Phase II clinical study in epilepsy, the company has been constantly exploring new avenues of research to progress its understanding of CBD. It is observing numerous evidence that bolsters the benefits of CBD for women looking for relief from menopausal and perimenopausal symptoms.

However, the Food Standards Agency (FSA) has a contradicting opinion over the use of CBD by expecting women. The regulator has warned breastfeeding mothers and pregnant women to restrict their CBD medications to no more than 70mg a day.

As for CBD businesses, the regulator warned that their products could hit the bins if they failed to clarify the contents and safety of their items by the end of March 2021. Meanwhile, manufacturers are requested to register themselves with the FSA for “novel food authorization”. This grade would help the public to gain perspective about the safety profile of CBD products.

Source Credit: https://finance.yahoo.com/news/satipharm-initiates-clinical-research-cbd-080000122.html



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...